Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline

被引：0
|
作者：
Kong, Hui [1 ]
Bai, Qianming [1 ]
Lu, Hongfen [1 ]
Zhou, Xiaoyan [1 ]
Yang, Wentao [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
185
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
    Wang, Bo
    Ding, Wei
    Sun, Ke
    Wang, Xiaoling
    Xu, Liming
    Teng, Xiaodong
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [32] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry
    Valerie J. Taylor
    Penny J. Barnes
    Sean C. Godwin
    Gillian C. Bethune
    Virchows Archiv, 2021, 479 : 23 - 31
  • [33] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+by immunohistochemistry
    Taylor, Valerie J.
    Barnes, Penny J.
    Godwin, Sean C.
    Bethune, Gillian C.
    VIRCHOWS ARCHIV, 2021, 479 (01) : 23 - 31
  • [34] Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
    Zhi-Hua Liu
    Kun Wang
    Dan-Yi Lin
    Jie Xu
    Jie Chen
    Xiao-Yu Long
    Yan Ge
    Xin-Lan Luo
    Ke-Ping Zhang
    Yan-Hui Liu
    Fang-Ping Xu
    Breast Cancer Research and Treatment, 2019, 175 : 51 - 57
  • [35] OXC1 Predicts HER2-FISH Status in Breast Cancers with Equivocal HER2 IHC Results
    Zuo, Ke
    Li, Ming
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 224 - +
  • [36] OXC1 Predicts HER2-FISH Status in Breast Cancers with Equivocal HER2 IHC Results
    Zuo, Ke
    Li, Ming
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 224 - +
  • [37] Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases
    Liu, Zhi-Hua
    Wang, Kun
    Lin, Dan-Yi
    Xu, Jie
    Chen, Jie
    Long, Xiao-Yu
    Ge, Yan
    Luo, Xin-Lan
    Zhang, Ke-Ping
    Liu, Yan-Hui
    Xu, Fang-Ping
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 51 - 57
  • [38] Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+Invasive Breast Cancer
    Yamada, Mai
    Kubo, Makoto
    Yamamoto, Hidetaka
    Yamashita, Nami
    Kai, Masaya
    Zaguirre, Karen
    Kaneshiro, Kazuhisa
    Shimazaki, Akiko
    Hayashi, Saori
    Kawaji, Hitomi
    Mori, Masaki
    Oda, Yoshinao
    Nakamura, Masafumi
    ANTICANCER RESEARCH, 2021, 41 (08) : 4143 - 4149
  • [39] Impact of the 2013 ASCO/CAP Guideline Recommendations for HER2Testing of Invasive Breast Carcinoma: A Focus on Tumors Assessed as Equivocal for HER2 Gene Amplification By FISH
    Bethune, Gillian
    van Zanten, Daniel Veldheijzen
    Younis, Tallal
    Rayson, Daniel
    Thompson, Kara
    Barnes, Penny
    LABORATORY INVESTIGATION, 2015, 95 : 35A - 35A
  • [40] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
12345